T he effects of critical illness may persist well after resolution of the acute critical illness as well as after discharge from the intensive care unit (ICU). This "chronically" critically ill population, many of whom require prolonged mechanical ventilation, is a population that has significant associated morbidity and cost (1) . Therefore, the "chronically" critically ill constitute an increasingly large and important population of patients. During the last decade, longterm acute care hospitals (LTAC) have been developed to provide care for patients with ongoing complex problems following hospitalization for a critical illness, such as long-term weaning from mechanically ventilation (2, 3) .
Although considerable data are available regarding red blood cell (RBC) transfusion practice in the ICU, few data are available on transfusion practice in critically ill patients after they leave the ICU. There are, however, some suggestions that at least some of these more "chronic" patients have ongoing RBC transfusion requirements after leaving the ICU. Recent studies have observed that 13% of patients followed for 30 days after ICU admission receive RBC transfusions after leaving the Context: Anemia is common in the critically ill and results in a large number of red blood cell transfusions. Recent data have shown that red blood cell transfusions in critically ill patients can be decreased with recombinant human erythropoietin (rHuEPO) therapy during their intensive care unit stay.
Objective: To assess the efficacy of rHuEPO therapy in decreasing the occurrence of red blood cell transfusions in patients admitted to a long-term acute care facility (LTAC).
Design: A prospective, randomized, double-blind, placebocontrolled, multiple-center trial.
Setting: Two long-term acute care facilities.
Patients: A total of 86 patients who met eligibility criteria were enrolled in the study with 42 randomized to rHuEPO and 44 to placebo.
Interventions: Study drug (rHuEPO 40,000 units) or a placebo was administered by subcutaneous injection before day 7 of long-term acute care facility admission and continued weekly for up to 12 doses.
Main Outcome Measures:
The primary efficacy end point was cumulative red blood cell units transfused. Secondary efficacy end points were the percent of patients receiving any red blood cell transfusion; the percent of patients alive and transfusion independent; cumulative mortality; and change in hematologic variables from baseline. Logistic regression was used to adjust the odds ratio for red blood cell transfusion. All end points were assessed at both study day 42 and study day 84. ICU (4, 5) . These patients, 40% of whom are transfused only following ICU discharge, on average receive almost 3 RBC units after leaving the ICU (5) .
Transfusion practice in the critically ill has been under considerable scrutiny during the last decade. Recent studies have raised the concern that immunomodulation related to allogeneic blood transfusion is associated with an increase in infections in the critically ill (6, 7) . Concerns have also been raised regarding possible increases in morbidity associated with the age of RBCs transfused (8) . Adding to the controversy about risk/benefit ratio for RBC transfusion are recent data showing that an aggressive RBC transfusion strategy may decrease the likelihood of survival in selected subpopulations of critically ill adults (9) . In the critically ill, RBC transfusion appears to be independently associated with increases in morbidity and mortality (4, 5) . Accordingly, limiting exposure to allogeneic RBC transfusions would be advantageous in the critically ill population, either acute or chronic.
Recently, in a large, randomized, placebo-controlled trial of critically ill patients admitted to the ICU, administration of a weekly dose of 40,000 units of recombinant human erythropoietin (rHuEPO) for up to four doses resulted in a 20% reduction in the total number of RBC units transfused (10) . The current study was designed to assess the efficacy of rHuEPO in reducing the exposure to allogeneic RBCs in chronically critically ill patients admitted to an LTAC. The objectives were to determine whether administration of rHuEPO to patients admitted to an LTAC would decrease the occurrence of any RBC transfusion as well as decrease the cumulative number of RBC units transfused.
METHODS
General Description. The study was a prospective, randomized, double-blind, placebocontrolled, multiple-center trial conducted at two LTACs between April 2000 and May 2002. Approval of the study was obtained from a central Institutional Review Board, Shulman Associates, and informed consent was obtained from each patient (or his or her surrogate). The Institutional Review Board determined who could qualify as a patient surrogate for the purpose of giving consent.
Patient enrollment was done at each site and supervised by one of the investigators. Randomization, study monitoring, and data analysis were done by a contract research organization (Battelle CRO). The investigators, with assistance from Battelle CRO, interpreted the data and were responsible for the manuscript. The final manuscript was reviewed by the study sponsor. The investigators determined the final manuscript content and had full access to all data.
Study Population. All patients admitted to either of two LTAC facilities were evaluated for entry into the study within 7 days of admission to the LTAC. Inclusion criteria included the following: admitted to the LTAC Յ7 days; age Ն18 yrs; hematocrit Ͻ38; male or female, female patients must be either postmenopausal for Ն1 yr or surgically sterile (hysterectomy or tubal ligation) or if of childbearing potential must have a negative pregnancy test (serum human chorionic gonadotropin radioimmunoassay) immediately before study entry; and signed informed consent by patient (or surrogate). Exclusion criteria were the following: renal failure on dialysis; uncontrolled hypertension (systolic blood pressure Ͼ200 or diastolic blood pressure Ͼ110) after adequate therapy; new onset (within 3 months) or seizures uncontrolled by medication; acute burns; pregnancy or lactation; acute ischemic heart disease (myocardial infarction or unstable angina); acute gastrointestinal bleed; prior treatment with rHuEPO; participation in another research protocol; and expected discharge or death within 7 days of LTAC admission.
Patients who met entry criteria and who gave informed consent were randomized and entered into the study during the first week of LTAC admission. Randomization was stratified by site and within each site stratified by whether or not the patient was ventilator-assisted. Randomization entailed use of computer-generated random numbers. The screening and enrollment flow is displayed in Figure 1 .
Study Design. Study drug (rHuEPO [Procrit, Ortho Biotech Products, L.P.] 40,000 units or a placebo identical in appearance) was administered by subcutaneous injection during the first week of LTAC admission and continued weekly for patients who remained in the LTAC, for a maximum of 12 doses (study days 1, 8, 15, etc.) . The study drug was discontinued if a patient was discharged before week 12. Syringes were prepared in the pharmacy. The study drug was held if the hematocrit was Ն38% before the scheduled administration. All patients were to be followed for a total of 84 days following randomization (study day 84). Patients were not followed following discharge from the LTAC. If a patient left the LTAC but then returned within the 84-day treatment period, treatment was to recommence based on the original study day schedule.
Patients received oral iron (liquid preparation), Ն150 mg of elemental iron per day, beginning on study day 1. Parenteral iron was to be given to patients demonstrating an inadequate response to oral iron (transferrin saturation Ͻ20% and a decrease of serum ferritin to Ͻ100 ng/mL).
The need for RBC transfusion was determined by a patient's physician. The following transfusion guideline was established for the study: No RBC transfusion if the hematocrit concentration is Ն24, unless there is a specific clinical indication (active bleeding, ischemia, or other); RBC transfusion for a hematocrit concentration Ͻ24 is at a physician's discretion. There was no hemoglobin level or hematocrit concentration that mandated an RBC transfusion. In addition, patients were monitored for all adverse events associated with either drug administration or RBC transfusion.
Study Outcomes. The primary efficacy end point was cumulative RBC units transfused. Secondary efficacy end points identified prospectively were the percent of patients receiving any RBC transfusion; the percent of patients alive and transfusion independent; cumulative mortality; and change in hematologic variables from baseline. All end points were assessed at both study day 42 and study day 84.
Baseline Assessment. At the time of randomization, baseline demographic and laboratory data were obtained. Admitting diagnosis was selected from a list of diagnostic categories; all that applied were noted. Comorbidities identified from the medical history included cardiac disease, chronic pulmonary disease, diabetes mellitus, hypertension, malignancy, peripheral vascular disease, primary hematologic disease, and thromboembolic disease.
Study Regimen and Follow-Up. Patients were followed until LTAC discharge or study day 84 if still in the LTAC. Adverse events were assessed daily. Laboratory data were obtained weekly, within 36 hrs before the weekly administration of study drug, and at study completion. Patients discharged from the LTAC before study day 84 or who died had final laboratory data obtained within 7 days of discharge or death. Mechanical ventilation was recorded on a daily basis, as was a patient's presence in the LTAC.
Statistical Analysis. Power considerations for the current study were based on assumptions regarding the distribution of transfusions generated from the limited data currently available. A sample size of 86 (43 subjects per group) was planned for this study. For the primary efficacy end point cumulative RBC transfusion, expressed as units transfused per 100 days alive, this sample size provides 80% power for detection of a reduction in transfusion requirement from 5.5 Ϯ 3.0 units per 100 days alive in the placebo group to 3.69 Ϯ 3.0 in the group receiving rHuEPO. The estimate of 5.5 units per 100 days alive is based on prior experience in this population. All patients were to be followed for 84 days, unless death occurred earlier. The analyses described subsequently were performed at both 42 days and 84 days, which were prospectively chosen. Analysis of outcomes was on an intention-to-treat basis.
The primary end point was cumulative RBC units transfused. The comparison of the number of RBC units transfused per patient in the two study groups entailed use of the WilcoxonMann-Whitney test. The transfusion rate for each group was expressed as RBC units transfused per day alive while in the study. This was determined by dividing the total number of RBC units transfused for each group by the total number of days alive for the patients in that group (sum of the number of days alive for each individual patient in the group, maximum of 84 for a patient surviving to study day 84).
The secondary efficacy end point, namely percent of patients transfused, was evaluated using a two-sided Fisher's exact test. Patients who were not transfused at the time of study withdrawal or lost to follow-up were considered not transfused for this analysis. In addition, a second analysis was done in which all patients withdrawn or lost to follow-up were considered transfused. A similar analysis was performed for the end point alive and transfusion-free. The analyses calculated an odds ratio and its 95% confidence intervals.
Several survival analyses of time to event (death, first transfusion, first transfusion or death) were performed in which Kaplan-Meier survival curves for the two groups were compared by the log rank test.
Mechanical ventilation was assessed by the number of days alive and off mechanical ventilator for those patients enrolled in the ventilator-assisted subgroup of patients. The difference between the two treatment groups in median number of days alive and off mechanical ventilator was tested using the WilcoxonMann-Whitney test (two-tailed). Additionally, the two treatment groups were compared with methods of survival analysis for time to ventilator discontinuation using Kaplan-Meier plots and the log rank test.
Logistic regression was performed to adjust the odds ratio for RBC transfusion. Covariates entered included age, gender, diagnostic categories, comorbidities, baseline hemoglobin, baseline iron studies, baseline erythropoietin level, and baseline serum creatinine.
To
Results are displayed as mean Ϯ SD, unless otherwise indicated. All statistical tests were two-tailed at the .05 significance level except for the tests of treatment-by-covariate interactions, which were at the .10 significance level.
RESULTS
Study Population. A total of 86 patients were enrolled in the study (39% of eligible patients) with 42 randomized to rHuEPO and 44 randomized to placebo (Fig. 1) . Of the remaining eligible patients, 28% were not approached for consent either because their social situation was believed by the investigator to be too unstable for appropriate consent or the investigators were not able to contact appropriate family members or surrogate. The two groups were generally comparable at enrollment with respect to baseline demographic characteristics and laboratory values as well as admitting diagnosis and comorbidities (Tables 1 and 2) . Only baseline hemoglobin level was significantly different between the placebo group and the rHuEPO group (placebo 9.3 Ϯ 1.4 vs. rHuEPO 9.9 Ϯ 1.2, p ϭ .02). Subsequent analysis adjusted for the baseline hemoglobin difference.
The median number of study drug doses patients received was 7.0 (quartile range,, 3-11 doses). In general, most subjects received the appropriate dose and there were relatively few dose administration protocol deviations. Dose administration protocol deviations were recorded for 14 (16.3%) patients (seven placebo and seven rHuEPO), with the most common being dose administration at the incorrect time. There was only one missed dose in an rHuEPO patient.
Blood Transfusions. The RBC transfusions for each treatment group during the course of the 42-day follow-up appear in Table 3 . Transfusion was initially assessed based on the total RBC units transfused per subject (median units per patient 2.0 vs. 0, p Ͻ .006). A second analysis that accounted for time at risk for transfusion demonstrated that the RBC transfusion rate per day alive was significantly lower in the rHuEPO group compared with the placebo group (0.026 vs. 0.057, p ϭ .0139). The ratio of RBC transfusion rates per day alive was 0.45 with 95% confidence interval (CI) of 0.14, 0.76, indicating a 54.8% relative reduction in transfusion burden for the rHuEPO group as compared with placebo. The total number of RBC units transfused with rHuEPO therapy as compared with placebo therapy was 40 units vs. 85 units, respectively.
The RBC transfusion data through study day 84 are also shown in Table 3 . The differences between the rHuEPO and placebo groups are less apparent at 84 days than at 42 days. The difference between the rHuEPO and placebo group is maintained, but does not increase, from study day 42 to study day 84. The median number of RBC units transfused is significantly lower in the rHuEPO group; however, transfusions per day alive were not significantly different between the rHuEPO and the placebo groups.
The percentage of patients who received any RBC transfusion at day 42 was significantly lower in the rHuEPO group compared with the placebo group (31% vs. 61%, p Ͻ .006; odds ratio 0.28, 95% CI, 0.12, 0.69). After adjustment for baseline characteristics by means of multiple logistic regression analysis, the statistically significant beneficial effect of rHuEPO was unchanged (adjusted odds ratio 0.35, 95% CI 0.14, 0.88). The results were similar at day 84 (41% vs. 64%, p ϭ .05; odds ratio 0.39, 95% CI, 0.16, 0.93); however, the adjusted odds ratio was not significant (0.47, 95% CI 0.19, 1.16). Analysis using a composite end point of time to first transfusion or death at either day 42 (66% placebo, 36% rHuEPO, p ϭ .005) or day 84 (68% placebo, 45% rHuEPO, p ϭ .005) was also similar to the previous analysis. Finally, when similar analyses were done in which all patients withdrawn or lost to follow-up were considered transfused, the significance of the findings did not change. Figure 2 shows a Kaplan-Meier plot of the time to first transfusion, which indicates that a difference between the two treatment groups commences near the end of the first week postrandomization. There is increasing separation between the two groups through the first 5-6 wks of therapy but no additional separation between study days 42 and 84, and the separation in fact decreases. There were differences in transfusion practice between the two treatment groups. The mean pretransfusion hemoglobin was 7.5 Ϯ 0.8 g/dL for the placebo group and 8.0 Ϯ 0.5 g/dL for the rHuEPO group (p Ͻ .04). More than 90% of RBC transfusions in the placebo group were administered at a hemoglobin level of Ͻ8 g/dL vs. 60% of transfusions in the rHuEPO group. Hematologic Variables. A mixed effect model for the longitudinal data of hemoglobin over time was performed to assess the hemoglobin rate of increase for each of the two treatment groups. Both treatment groups showed an increase in hemoglobin levels during the course of the study with a rate of increase 0.017 g/(dL·day) for the rHuEPO group and 0.006 g/(dL·day) for the placebo group (Fig. 3) . The difference (0.011 g/[dL·day]) in the rates of increase between the two treatment groups in hemoglobin levels was statistically significant (p ϭ .045). The mean change from baseline to final hemoglobin was 1.0 Ϯ 2.0 in the rHuEPO group and 0.4 Ϯ 1.7 g/L in the placebo group with final hemoglobin levels of 10.9 Ϯ 2.1 g/dL and 9.8 Ϯ 1.5 g/dL, respectively.
There was an increase in reticulocyte percent observed in the rHuEPO group that peaked on study day 14, which was not observed in the placebo group. However, at the time of the final reticulocyte determination, both treatment groups had mean percent reticulocyte values that were similar to those observed at baseline. There were small decreases in iron parameters in the rHuEPO group observed during the course of the study. On the other hand, no changes in iron parameters were observed in the placebo group.
Mortality/Adverse Events. There were no statistically significant differences between the two groups in either 42-day or 84-day mortality (42 day mortality 11.9% rHuEPO vs. 22.7% placebo, p ϭ .26; 84-day mortality 19.0% rHuEPO vs. 29.5% placebo, p ϭ .17; RR 0.55, 95% CI 0.21-1.43). The numbers of subjects with at least one serious adverse event (32% placebo vs. 38% rHuEPO, p ϭ .65) as well as specific adverse events reported were comparable between the two treatment groups.
Mechanical Ventilation. Approximately half of the subjects were receiving mechanical ventilation at the time of enrollment (24 of 44 [54.5%] placebo, 23 of 42 [54.8%] rHuEPO). Most of the subjects remained on the ventilator throughout the study period. By day 84, only seven (29%) of the placebo subjects and four (17.0%) of the rHuEPO subjects had been weaned off of the ventilator. There were no statistically significant differences in analyses of treatment comparability related to ventilator usage. Subjects who were not mechanically ventilated overall received less RBC transfusions then ventilated subjects; however, the rHuEPO group still received fewer RBC transfusions.
Hospital Length of Stay. The median time based on Kaplan-Meier plots from day 1 to the time of LTAC discharge was 62.0 days in the placebo group and 68.5 days in rHuEPO group (p ϭ .86, based on the log-rank test).
DISCUSSION
The present study suggests that chronically critically ill patients admitted to LTAC are anemic and have an ongoing transfusion requirement that persists during their LTAC stay. Treatment with 40,000 units of rHuEPO given weekly resulted in both a significant decrease in the percent of patients transfused and a trend to a reduction in the total number of RBCs transfused compared with placebo treatment. Despite the reduction in the number of RBC transfusions, the increase in hemoglobin level was significantly greater with rHuEPO therapy.
Previous studies have demonstrated that critically ill patients admitted to the ICU are anemic and as a consequence receive a large number of RBC transfusions during their ICU course (4, 5) . The current study demonstrates that this is also true for a more chronically critically ill population. Baseline hemoglobin level in LTAC patients was approximately 9.5 g/dL, consistent with prior observations of patients 30 days after ICU admission (5) . Approximately 60% of placebo patients admitted to LTAC received one or more RBC transfusions during their LTAC admission. Overall, during the 12 wks of follow-up, LTAC patients were transfused on average 1-2 RBC units per month. Although the total transfusion burden in chronic critically ill patients is much less than that observed in ICU patients (4, 5, 10) , similar to the ICU patients (10, 11) LTAC patients respond to the administration of rHuEPO.
Most of the transfusion benefit observed with rHuEPO treatment took place in the first 42 days of the study. However, the increase in hemoglobin level continued to be greater in the rHuEPO group through study day 84. The observation that most of the transfusion benefit occurs by day 42 may simply reflect the relatively small number of patients remaining in the LTAC, and therefore at risk for transfusion, beyond day 42. The small number of patients remaining in the LTAC past day 42 limits the conclusions that can be drawn regarding the impact of treatment between days 42 and 84. However, the continued hemoglobin effect in the rHuEPO group suggests a continued effect of rHuEPO.
Clearly, transfusion practice could have an impact on the results and the magnitude of any potential benefit resulting from rHuEPO therapy. Recently, it has been shown that a transfusion strategy in the critically ill to maintain a hemoglobin level between 7 and 9 g/dL is as effective as, and in some cases superior to, a transfusion strategy to maintain a hemoglobin level between 10 and 12 g/dL (9) . However, recent reports suggest that the "transfusion threshold" in most ICUs remains higher, at 8.4 -8.6 g/dL, than the more conservative transfusion strategy (4, 5) . In the current study, RBC transfusion practice was more restrictive (lower transfusion threshold) than the recent data on current practice in the ICU and more consistent with restrictive strategy in the TRICC trial (9) . In fact, the pretransfusion hemoglobin in the placebo group (7.5 g/dL) was significantly lower than the pretransfusion hemoglobin in the rHuEPO group (8.0 g/dL). This resulted in Ͼ90% of transfusions in the placebo group given at a hemoglobin level Ͻ8.0 g/dL vs. 60% of transfusions in the rHuEPO group. The transfusion of placebo subjects at lower hemoglobin levels than rHuEPO subjects, if anything, would tend to decrease the transfusion differences observed in the current study and offset any effect in favor of fewer transfusions in the rHuEPO group resulting from the higher baseline hemoglobin level in these patients. The multivariate analysis was adjusted for baseline hemoglobin level, which did not affect the significance of the transfusion benefit of rHuEPO.
Patients are anemic on admission to the LTAC. Erythropoietin levels in the LTAC patients are lower than would be expected based on the degree of anemia observed, which is similar to what has been previously described in more acutely critically ill patients (12) (13) (14) (15) . On the other hand, the iron level and transferrin saturation observed in the LTAC patient are higher than have been reported in the acutely critically ill (10, 13, 15) , whereas ferritin level is similarly elevated in the two populations. Our finding of a marked response to pharmacologic doses of erythropoietin supports the concept that the chronically critically ill patient, similar to the acutely critically ill patient, has a blunted erythropoietic response to physiologic stimuli as well as an impaired ability to respond to endogenous erythropoietin.
In the present study there were no significant differences in morbidity or mortality observed between the two groups; however, this study was not powered to detect such differences. Other studies of rHuEPO therapy in critically ill patients admitted to the ICU have also failed to demonstrate clinical outcome differences associated with RBC transfusion reduction (10, 11) . These studies, although larger, still did not have the power to identify small differences in clinical outcomes. In addition, to the extent that the risk associated with RBC transfusion is reduced (e.g., leukoreduction) (16) , the ability to detect significant differences in clinical outcome resulting from transfusion reduction will be more difficult. Further study is necessary to determine whether there are clinical outcome benefits associated with the reduction in the exposure to RBC transfusion with rHuEPO administration in critically ill patients admitted to either the ICU or LTAC.
There was also no increase in the number of serious adverse clinical events observed with rHuEPO therapy in the current study. This is consistent with prior studies of rHuEPO therapy in the critically ill (10, 11) . However, as with clinical outcomes, the study does not have the power to identify less common adverse events. Recently, the occurrence of pure red-cell aplasia associated with the presence of antierythropoietin antibodies was reported in a small number of chronic renal failure patients treated with rHuEPO administered subcutaneously (17, 18) . This phenomenon was not observed in this trial or prior trials in the critically ill; however, the follow-up periods in these studies were relatively short (10, 11) .
The 50% percent reduction of RBC transfusions in LTAC patients is higher than observed in patients treated with rHuEPO in the ICU; however, the reduction in total number of RBC units transfused was more modest in LTAC patients (11) . This, at least in part, reflects the smaller overall transfusion requirement in patients post-ICU. Most of the effect of rHuEPO observed in this study occurred by day 42. Therefore, although the median number of rHuEPO doses given to patients in the study was seven, limiting therapy in LTAC patients to only 6 wks (six doses) rather than 12 wks (12 doses) may be a consideration. None of the patients in the current study received rHuEPO before LTAC admission. How prior rHuEPO therapy in the ICU would affect subsequent rHuEPO response in the LTAC is unclear. Strategies to approach rHuEPO therapy throughout the course of a patient's critical illness, both in the ICU and following ICU discharge, will need to be developed and studied.
Establishing the cost-effectiveness of rHuEPO therapy in large part depends on whether there is a benefit in clinical outcome achieved by the reduction in RBC transfusions. This clinical benefit could result from a reduction in the number of RBC units transfused (e.g., avoiding transfusion related adverse events), from a direct effect of rHuEPO, or from achievement of a higher hemoglobin level. In addition, the reduction in the number of RBC units transfused may itself be of substantial benefit, independent of any associated clinical outcome effects (e.g., saving a scarce resource). A recent study attempted to provide estimates of incremental costs associated with averting rare transfusion-related adverse events by treating critically ill patients with rHuEPO (19) . In this study, because rare adverse events were chosen as outcomes, rHuEPO did not appear to be economically attractive. However, rHuEPO would be economically attractive if it was shown to be associated with improved clinical outcomes or prevented common complications from RBC transfusions such as pulmonary edema. It would also be cost-effective in an environment where RBCs were very scarce or potentially contaminated to a greater degree by known or unknown pathogens. Finally, rHuEPO would be a more economically attractive alternative if the cost of RBCs continues to increase as it has during recent years as new strategies to eliminate known transfusion-related infection and to screen for new infections have been implemented (20) . For LTAC patients, since most of the effect of rHuEPO appears to occur by day 42, limiting therapy in these patients to 6 wks might be the most cost-effective strategy.
